Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could shrink HER2 breast tumors before surgery

NCT ID NCT07196774

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times

Summary

This study tests a new drug called SHR-A1811 against a standard combination of chemotherapy and targeted drugs for women with early-stage or locally advanced HER2-positive breast cancer. About 740 women will receive either the new drug or the standard treatment before surgery. The main goal is to see if the new drug leads to a higher rate of complete tumor disappearance by the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-STAGE OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shengjing Hospital, China Medical University

    RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

EARLY-STAGE OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER